Targeting residual inflammatory risk as a strategy to lower CV riskAug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)
CSI ROME Nicole Jaspers and Manon Slob (both Utrecht, The Netherlands) interview Prof. Paul Ridker (Boston, MA, USA) about the concept of residual risk and how the different forms may be targeted with novel therapeutic strategies to further lower CV risk.
- Residual CV risk comes in different forms 0:17
- Therapeutic strategies to lower residual inflammatory CV risk 1:06
- Endpoints of interest in clinical trials testing the inflammation hypothesis 2:51
- Interaction between lipid-lowering and anti-inflammatory effects of therapies 3:43
In the Cardiovascular Scene Investigation (CSI) series, young clinicians with an investigative mindset interview experts about the context and meaning of the results they just presented at the ESC congress.
The series is aimed to explore the background and practical implications of recent scientific developments, like those discussed in a session on residual risk at the ESC Congress 2016, with speakers in this session.
Faculty & Disclosures
Paul Ridker - Eugene Braunwald Professor of Medicine, Director of the Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Nicole Jaspers and Manon Slob - UMC Utrecht, The Netherlands
The speakers did not receive financial compensation for participating in these interviews